焦宇辰，中國醫(yī)學科學院腫瘤醫(yī)院研究員，博士生導師。1995年北京大學生命科學院協(xié)和醫(yī)學預(yù)科，2003年在中國協(xié)和醫(yī)科大學八年制臨床醫(yī)學專業(yè)獲醫(yī)學博士(MD)學位，2009年在Johns Hopkins大學獲生物化學博士(PhD)學位。2010年進入Johns Hopkins大學Ludwig癌癥研究所進行博士后研究，主要研究腫瘤基因組。2013年加入中國醫(yī)學科學院腫瘤醫(yī)院，從事腫瘤基礎(chǔ)及轉(zhuǎn)化研究。

基于多種組學及生物信息學分析腫瘤分子改變時空異質(zhì)性及腫瘤分子分型；基于CRISPR-Cas9協(xié)同致死篩選的功能基因組研究，發(fā)現(xiàn)針對驅(qū)動基因突變的新靶點、新藥物；基于ctDNA多組學標志物的腫瘤液體活檢技術(shù)在腫瘤早篩和療效評估的應(yīng)用。

午夜92福利1000,午夜92福利1000,久久国产亚洲高清观看5388,美女不拍网站免费观看,欧美***天天久久综合精品,中文字幕日韩系列中文字幕,综合久久国产九一剧情麻豆,丰满人妻在线免费视频,奶子大逼又嫩操起来真爽

1. Wang P#, Song Q#, Ren J#, Zhang W#, Wang Y, Zhou L, Wang D, Chen K, Jiang L, Zhang B, Chen W, Qu C*, Zhao H*, Jiao Y*. Simultaneous analysis of mutations and methylations in circulating cell-free DNA for hepatocellular carcinoma detection. Science Translational Medicine. 2022;14(672): eabp8704. (IF=19.319)

2. Ma Y#, Zhu Q#, Wang X#, Liu M, Chen Q, Jiang L, Chi Y, Zeng YX*, Zhao H*, Jiao Y*. Synthetic lethal screening identifies DHODH as a target for MEN1-mutated tumor cells. Cell Research. 2022, 32(6):596-599. (IF=46.297)

3. Zhao D#, Yue P#, Wang T#, Wang P#, Song Q, Wang J, Jiao Y*. Personalized analysis of minimal residual cancer cells in peritoneal lavage fluid predicts peritoneal dissemination of gastric cancer. Journal of Hematology Oncology. 2021, 14(1):164. (IF=23.168)

4. Fujikura K#, Hosoda W#, Felsenstein M#, Song Q#, Reiter JG,  Zheng L, Beleva Guthrie V, Rincon N, Dal Molin M, Dudley J, Cohen JD, Wang P, Fischer CG, Braxton AM, No? M, Jongepier M, Fernández-Del Castillo C, Mino-Kenudson M, Schmidt CM, Yip-Schneider MT, Lawlor RT, Salvia R, Roberts NJ, Thompson ED, Karchin R, Lennon AM, Jiao Y*, Wood LD*. Multiregion whole-exome sequencing of intraductal papillary mucinous neoplasms reveals frequent somatic KLF4 mutations predominantly in low-grade regions. Gut. 2021, 70(5):928-939. (IF=31.793)

5. Zhu Q#, Ma Y#, Wei Z#, Li M, Zhang Y, Liu M, He H, Qu C, Cai J, Wang X*, Zeng Y*, Jiao Y*. AHR mediates the aflatoxin B1 toxicity associated with hepatocellular carcinoma. Signal Transduction Targeted Therapy. 2021, 6(1):299. (IF=38.104)

6. Liang J#, Zhao H#, Diplas BH#, Liu S#, Liu J, Wang D, Lu Y, Zhu Q, Wu J, Wang W, Yan H, Zeng YX*, Wang X*, Jiao Y*. Genome-Wide CRISPR-Cas9 Screen Reveals Selective Vulnerability of ATRX-Mutant Cancers to WEE1 Inhibition. Cancer Research. 2020, 80(3):510-523. (IF=12.701)

7. Qu C#*, Wang Y#, Wang P#, Chen K#, Wang M#, Zeng H#, Song Q, Diplas BH, Tan D, Fan C, Guo Q, Zhu Z, Yin H, Jiang L, Chen X, Zhao H, He H, Wang Y, Li G, Bi X, Zhao X, Chen T, Tang H, Lv C, Wang D, Chen W, Zhou J, Zhao H, Cai J, Wang X, Wang S, Yan H, Zeng YX, Cavenee WK*, Jiao Y*. Detection of early-stage hepatocellular carcinoma in asymptomatic HBsAg-seropositive individuals by liquid biopsy. Proc Natl Acad Sci U S A. 2019, 116(13):6308-6312. (IF=9.412)

8. Huang J*, Xu B*, Mo H, Zhang W, Chen X, Wu D, Qu D, Wang X, Lan B, Yang B, Wang P, Zhang H, Yang Q, Jiao Y*. Safety, activity and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clinical Cancer Research. 2018, 24(6):1296-1304. (IF=8.911, C100)

9. Zhang W#, He H#, Zang M#, Wu Q#, Zhao H#, Lu L#, Ma P, Zheng H, Wang N, Zhang Y, He S, Chen X, Wu Z, Wang X, Cai J, Liu Z, Sun Z, Zeng YX*, Qu C*, Jiao Y*, Genetic Features of Aflatoxin-associated Hepatocellular Carcinomas. Gastroenterology. 2017, 153(1):249-262. (IF=20.773)

10. Jiao Y#, Shi C#, Edil BH, de Wilde RF, Klimstra DS, Maitra A, Schulick RD, Tang LH, Wolfgang CL, Choti MA, Velculescu VE, Diaz LA Jr, Vogelstein B*, Kinzler KW*, Hruban RH*, Papadopoulos N*. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science. 2011, 331(6021):1199-203. (IF=31.201, C100, ESI, R)